

Patient ID SA00167524	Patient Name ATLASAB, NGHIS	Birth Date 1966-04-03	Sex F	Age 58
Order Number SA00167524	Client Order Number SA00167524	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7234570 SQA Manual Account		Collected 03 Apr 2024 11:55		

Histiocytic Neoplasms, NGS, V

Specimen Type

Peripheral blood

MCR

Indication for Test

NA

MCR

Pathogenic Mutations Detected

1. KRAS: Chr12(GRCh37):g.25398285C>A;
NM_033360.3(KRAS):c.34G>T; p.Gly12Cys (12%)

MCR

No other pathogenic mutations were detected in the other genes tested on the panel. See below for Variants of Unknown Significance and Additional Information. Please see the section of "Panel Gene List" below for the complete list of genes tested.

Interpretation

1. KRAS: Chr12(GRCh37):g.25398285C>A;
NM_033360.3(KRAS):c.34G>T; p.Gly12Cys (12%)

MCR

Normal gene/protein function: The KRAS gene, located on chromosome 12p12.1, encodes a member of the RAS family of membrane proteins that bind GDP/GTP and possess GTPase activity. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAS/RAF/MEK/ERK kinase (MAPK) and PI3K/AKT/mTOR pathways (Pylayeva-Gupta et al., 2011, 21993244; Kahn et al., 1987, 3310850).

Mutation effect: The c.34G>T (p.Gly12Cys) missense variant occurs at a known mutational hotspot and has been found in multiple tumor types (<https://cancer.sanger.ac.uk/cosmic>; <http://www.cbioportal.org>; <https://research.themmr.org>; Chang et al., 2016, 22619011/Change et al., 2018, 29247016; Gao et al., 2017, 28115009). KRAS mutations, primarily those occurring at codons 12, 13, and 61, result in constitutive activation of the RAS GTPase and the downstream RAF/MEK/ERK kinase and PI3K/AKT/mTOR pathways, leading to increased cellular proliferation and tumorigenesis (Brown et al., 2005, 1591308; Pylayeva-Gupta et al., 2011, 21993244).

Disease associations: KRAS mutations have been reported in approximately 25% of Rosai-Dorfman disease (RDD), 4–6% of Erdheim-Chester disease (ECD) or disseminated juvenile xanthogranuloma (JXG), 10–20% of histiocytic sarcoma, and 2% of Langerhans cells histiocytosis (LCH) (Durham et al., 2019, 31768065; Goyal et al., 2020, 32187362; Egan et al., 2020, 31439678, Shanmugam et al., 2019, 30626916; Massoth et al., 2021, 33904632). They have also been described in about 10% of Interdigitating dendritic cell sarcoma (IDCS) and 40% of Langerhans cell sarcoma (LCS) in a study with small disease cohorts (Massoth et al., 2021, 33904632). The clinical outcome impact of KRAS mutations has not been clearly demonstrated in histiocytic or dendritic cell neoplasms.

Therapeutic implications: The Food and Drug Administration (FDA) recently approved sotorasib, a RAS GTPase family inhibitor, for adult patients with KRAS G12C-mutated non-small cell lung cancer. Activating KRAS mutations may predict sensitivity to MAPK and PI3K/AKT/mTOR pathway inhibitors. Multiple inhibitors of MEK, PI3K, AKT and mTOR are currently in clinical trials for cancers. The mTOR inhibitors everolimus and temsirolimus have received FDA approval in solid tumors. MEK inhibitors have shown efficacy in preclinical studies

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Report Status: Final

Patient ID SA00167524	Patient Name ATLASAB, NGHIS	Birth Date 1966-04-03	Sex F	Age 58
Order Number SA00167524	Client Order Number SA00167524	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7234570 SQA Manual Account		Collected 03 Apr 2024 11:55		

(Janakiraman et al., 2010, 20570890; Gilmartin et al., 2016, 21245089). MEK inhibitor Cobimetinib is recommended in histiocytic neoplasms harboring a non-BRAF V600E MAPK pathway activating mutation, such as a KRAS mutation (NCCN guidelines, version 2.2021, Histiocytic neoplasms), supported by the efficacy observed in clinical trials and case studies (Diamonds et al., 2019, 30867592; Cohen et al., 2018, 27711968). One recent study showed that inhibition of SOS1, a KRAS activator and feedback node, along with MEK inhibition resulted in tumor regression in multiple mutant KRAS-driven cancer models (Hofmann et al., 2021, 32816843). Additional information about available clinical trials can be found at ClinicalTrials.gov.

Variants of Unknown Significance

MCR

None.

The VUS variants listed here (with approximate variant allele %) are not sufficiently characterized in the current literature and therefore are of uncertain or unknown clinical significance at this time. They are reported here for future reference in the event they become clinically significant in light of new scientific data.

Additional Information

MCR

None.

Clinical Trials

MCR

Information regarding possible clinical trials for this patient can be found at the following sites:

- 1). ClinicalTrials.gov:
<http://clinicaltrials.gov/ct2/search/advanced>
- 2). Mayo Clinic:
<http://www.mayo.edu/research/clinical-trials>
- 3). National Cancer Institute:
<http://www.cancer.gov/clinicaltrials/search>
- 4). The Leukemia and Lymphoma Society's Clinical Trial Support Center: <https://www.hematology.org/education/clinicians/clinical-trial-support-center>

Method Summary

1 MCR

A portion of the testing process was performed at Mayo Clinic Laboratories site.

DNA is extracted from validated specimen sources. Library preparation for Next Generation Sequencing (NGS) is performed followed by probe hybridization and capture. Sequencing of the final sample library is performed on a NGS instrument. Following bioinformatic processing of the sequencing data, the sequencing results are interpreted to provide a final clinical report. Genomic alterations are called according to human genome reference build GRCh37 (hg19).

Performance characteristics of NGS panel:

Single base substitutions: accuracy >99%; reproducibility >99% (intra- and interassay); sensitivity 5% variant allele fraction with a minimum depth of coverage of 500X.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Patient ID SA00167524	Patient Name ATLASAB, NGHIS	Birth Date 1966-04-03	Sex F	Age 58
Order Number SA00167524	Client Order Number SA00167524	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7234570 SQA Manual Account		Collected 03 Apr 2024 11:55		

Insertion/deletion events (less than or equal to 1000 bps in size): accuracy 100%; reproducibility >99% (intra- and interassay); sensitivity 5% variant allele fraction with a minimum depth of coverage of 500X. Some genetic or genomic alterations such as very large insertion/deletion events, copy number alterations (CNA) and gene translocation events are not detected by this assay.

Disclaimer

MCR

CLINICAL DISCLAIMER

Mutation calls detected between 5–10% variant allele fractions (VAF) may indicate low-level (i.e. subclonal) tumor populations, although the clinical significance of these findings may not be clear. Some apparent mutations classified as VUS may represent rare or low frequency polymorphisms. Prior treatment for hematologic malignancy could affect the results obtained in this assay. In particular, prior allogeneic hematopoietic stem cell transplant (HSCT) may cause difficulties in resolving somatic or polymorphic alterations, or in assigning variant calls correctly to donor and recipient fractions, if pertinent clinical or laboratory information (e.g. chimerism engraftment status) is not provided. Multiple additional factors may also impact the observed VAF including copy number alterations of the genetic locus, chromosome ploidy changes or subclonal composition. Correlation with clinical, histopathologic and additional laboratory findings is required for final interpretation of these results. This assay does not distinguish between somatic and germline alterations in analyzed gene regions, particularly with VAF near 50% or 100%. If nucleotide alterations in genes associated with germline mutation syndromes are present and there is also a strong clinical suspicion or family history of malignant disease predisposition, additional genetic testing and appropriate counseling may be indicated. This report interpretation is based on current medical and scientific literature, but clinical significance may not be completely established for all reported target gene abnormalities identified. The final interpretation of results for clinical management of the patient is the responsibility of the managing physician. At this time, it is not standard practice for the laboratory to systematically review likely pathogenic variants or variants of uncertain significance that have been previously detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time.

TECHNICAL DISCLAIMER

The depth of sequencing coverage may be variable for some target regions, but assay performance below the minimum acceptable criteria, or for failed regions is noted. Analysis of rare (low allele frequency) polymorphisms may be problematic in some cases. A low tumor cell percentage in the sample may affect the true mutation VAF and/or sensitivity. Suboptimal-performing regions (i.e. less than the expected minimum depth of coverage) may affect analytic sensitivity for detecting lower level mutations. In the rare event of suboptimal measured DNA input quantity for library preparation (e.g. due to limited tissue amount), detection sensitivity for subclonal variants near the assay limit of detection may be decreased, despite the presence of otherwise acceptable sequencing quality metrics. This is a qualitative test. The variant read fractions are provided for information only and represent a relative proportion of mutated alleles, but do not indicate a measure of analytical sensitivity for the given genes; assay sensitivity is as stated in the method summary. Some genetic or genomic alterations, such as very large insertion/deletion events, copy number alterations (CNA) and gene translocation events are not detected by this assay.

Panel Gene List

MCR

ARAF (NM_001654.4) Exons 7, 10–16, BRAF (NM_004333.4) Exons 11–18, CSF1R (NM_005211.3) Exons 8, 10, 12, 22, KRAS (NM_033360.3) Exons 2–4, MAP2K1 (NM_002755.3) Exons 2–3, 6, NRAS (NM_002524.4) Exons 2–4, PIK3CA (NM_006218.2) Exons 2–11, 14–21, PTEN (NM_000314.4) Exons 1–8.

For some genes, the transcript IDs used in the analysis may not be the same as in other cancer mutation databases, such as COSMIC <http://cancer.sanger.ac.uk/cosmic>

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292



Patient ID SA00167524	Patient Name ATLASAB, NGHIS	Birth Date 1966-04-03	Sex F	Age 58
Order Number SA00167524	Client Order Number SA00167524	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7234570 SQA Manual Account		Collected 03 Apr 2024 11:55		

Reviewed By

MCR

Signing Pathologist: SHANDA VOELTZ

NGHIS Result

MCR

See Interpretation

Received: 03 Apr 2024 13:32

Reported: 03 Apr 2024 13:44

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292